Skip to content

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

A single-cell atlas of large B cell lymphomas reveals distinct malignant archetypes predictive of clinical outcomes.

Large B cell lymphomas (LBCLs) exhibit significant heterogeneity which leads to disparate treatment response, with up to 40% of patients developing refractory disease or relapsing within the first two years. To understand the cellular and molecular basis of this heterogeneity, we performed single-cell RNA-seq, BCR-seq,...

S. Baaklini, A. Sarrabay, C. Barthelemy et al. · 0 citations
Open access Nov 2026

Co-targeting PARP and SHP2 Overcomes Resistance to Apoptosis and Induces Durable Responses in Breast Cancer.

Resistance to therapeutic interventions contributes to poor long-term cancer patient outcomes. Adaptation to therapy, a common mechanism of drug resistance involving drug-induced activation of pro-survival oncogenic processes, poses a challenge for the implementation of effective precision therapies. Here, we addressed...

Augustin Luna, He-Ping Wang, Lin Wang et al. · 0 citations
Open access Oct 2026

Key Challenges on the Path toward Precision Immunotherapy for Large B-cell Lymphoma.

Cell and immune therapies have transformed the outcomes of patients with lymphoma, but the majority of patients do not have durable benefit. Here, we provide our perspective on key challenges in personalizing cell and immune therapy approaches for lymphoma through discovery, validation, and clinical deployment of micro...

Xu-Bin Li, Christopher R. Flowers, Michael R. Green · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.